144 related articles for article (PubMed ID: 34811955)
1. Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium.
Boinpally R; Lu K
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):270-277. PubMed ID: 34811955
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
[TBL] [Abstract][Full Text] [Related]
5. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
Ankrom W; Bondiskey P; Li CC; Palcza J; Liu W; Dockendorf MF; Matthews C; Panebianco D; Reynders T; Wagner JA; Jakate A; Mesens S; Kraft WK; Marcantonio EE
Clin Transl Sci; 2020 May; 13(3):462-472. PubMed ID: 31899602
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetic interactions and safety of atogepant coadministered with esomeprazole.
Boinpally R; Butler M; Rojo J; Borbridge L; Wangsadipura V; Papinska A
Pain Manag; 2023 Jun; 13(6):351-361. PubMed ID: 37424270
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults.
Boinpally R; Trugman J
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):688-695. PubMed ID: 38261231
[TBL] [Abstract][Full Text] [Related]
12. Ubrogepant for the treatment of migraine.
Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
[TBL] [Abstract][Full Text] [Related]
13. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
17. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
[TBL] [Abstract][Full Text] [Related]
18. Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Boinpally R; Lu K
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):857-864. PubMed ID: 35174666
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
20. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Nedd M; Garland S; Falk N; Wilk A
Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
